中东和非洲单克隆抗体市场预测至 2028 年 - COVID-19 影响和区域分析（按来源（人、人源化、嵌合和鼠）、生产方法（体外和体内）、适应症（癌症、自身免疫性疾病） 、传染病、炎症性疾病、微生物疾病等）、应用（治疗应用、诊断应用和研究应用）、最终用户（医院、研究所等）
No. of Pages: 152 | Report Code: TIPRE00028620 | Category: Life Sciences
No. of Pages: 152 | Report Code: TIPRE00028620 | Category: Life Sciences
沙特阿拉伯对单克隆抗体产品的需求不断增长临床开发成功率高，据报道，FDA 在 1 期开发中批准 mAB 的概率约为 14.1%，几乎是小分子药物批准率（约 7.6%）的两倍。另一方面，IAVI 报告指出，随着全球大流行的爆发，许多生物制药公司以实惠的价格销售基于 mAB 的产品。例如，在南非，罗氏公司销售其乳腺癌单克隆抗体“曲妥珠单抗”，既作为赫赛汀的原始品牌，又作为第二品牌名为“Hercelon”。除此之外，由于这些单克隆抗体的供应有限，各制药公司正在中等收入国家进行临床试验。例如，默克公司正在南非、哥伦比亚和马来西亚等几个中等收入国家进行临床试验。上述因素对区域市场产生了积极影响，从而见证了中东和非洲地区在 COVID-19 大流行期间单克隆抗体的高度采用。
新的功能和技术，供应商可以吸引新客户并扩大他们在新兴市场的足迹。这一因素可能会推动单克隆抗体市场。中东和中东地区非洲单克隆抗体市场预计在预测期内将以良好的复合年增长率增长。
Strategic insights for Middle East and Africa Monoclonal Antibodies involve closely monitoring industry trends, consumer behaviours, and competitor actions to identify opportunities for growth. By leveraging data analytics, businesses can anticipate market shifts and make informed decisions that align with evolving customer needs. Understanding these dynamics helps companies adjust their strategies proactively, enhance customer engagement, and strengthen their competitive edge. Building strong relationships with stakeholders and staying agile in response to changes ensures long-term success in any market.
| Report Attribute | Details |
|---|---|
| Market size in 2021 | US$ 3,198.9 Million |
| Market Size by 2028 | US$ 5,741.1 Million |
| Global CAGR (2021 - 2028) | 8.7% |
| Historical Data | 2019-2020 |
| Forecast period | 2022-2028 |
| Segments Covered |
By 来源
|
| Regions and Countries Covered | 中东和非洲
|
| Market leaders and key company profiles |
The regional scope of Middle East and Africa Monoclonal Antibodies refers to the geographical area in which a business operates and competes. Understanding regional nuances, such as local consumer preferences, economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved regions or adapting their offerings to meet regional demands. A clear regional focus allows for more effective resource allocation, targeted marketing, and better positioning against local competitors, ultimately driving growth in those specific areas.
The Middle East and Africa Monoclonal Antibodies Market is valued at US$ 3,198.9 Million in 2021, it is projected to reach US$ 5,741.1 Million by 2028.
As per our report Middle East and Africa Monoclonal Antibodies Market, the market size is valued at US$ 3,198.9 Million in 2021, projecting it to reach US$ 5,741.1 Million by 2028. This translates to a CAGR of approximately 8.7% during the forecast period.
The Middle East and Africa Monoclonal Antibodies Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the Middle East and Africa Monoclonal Antibodies Market report:
The Middle East and Africa Monoclonal Antibodies Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The Middle East and Africa Monoclonal Antibodies Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the Middle East and Africa Monoclonal Antibodies Market value chain can benefit from the information contained in a comprehensive market report.
Office No. 1011, First floor, Farena Corporate Park, Magarpatta-Mundhwa road, Pune - 411028, Maharashtra, India
US:+16467917070
sales@businessmarketinsights.com
Get Free Sample For Middle East and Africa Monoclonal Antibodies Market
